Stevens-Johnson Syndrome Induced by Vandetanib
Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival....
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Korean Dermatological Association; The Korean Society for Investigative Dermatology
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276793/ |